On April 13, 2026, the federal government is negotiating a settlement regarding Amazon.com Inc.'s AMZN -0.62% treatment of delivery drivers, potentially avoiding a significant ruling on its employment status. The National Labor Relations Board (NLRB) has been pursuing Amazon since 2024 for allegedly violating drivers' rights linked to a former contractor in California. The NLRB claimed Amazon acted as a "joint employer," which would require it to engage in union negotiations. While Amazon has denied wrongdoing, a proposed settlement would offer two weeks' pay to up to 84 affected workers without admitting liability. This resolution could significantly impact ongoing legal proceedings.
Monday, April 13, 2026
ImageneBio announces $30 million private placement
ImageneBio announces $30 million private placement of pre-funded warrants with institutional investors to fund IMG-007 development
- Proceeds will support ongoing development of lead drug candidate IMG-007 for atopic dermatitis and alopecia areata.
CVRx sees preliminary Q1 2026 revenue of $14.7–$14.8 million, about 20% higher year over year
- Company reports first site activation in its BENEFIT-HF trial.
AdaptHealth closes $1.1B senior secured credit facility, extends debt to 2031
lowers borrowing costs, increases revolver capacity
- 2026 guidance remains unchanged following the new $1.1 billion senior secured credit facility.
Regeneron, Telix Pharmaceuticals to co-develop radiopharmaceutical cancer therapies
in 50/50 collaboration with $40M upfront, up to $2.1B milestones plus royalties
- Collaboration uses a 50/50 cost and profit-sharing model between Regeneron and Telix Pharmaceuticals.
- Approval expands Dupixent’s EU label for chronic spontaneous urticaria to children aged 2 to 11.
Stryker enters definitive agreement to acquire Amplitude Vascular Systems
adding next-generation intravascular lithotripsy platform to peripheral vascular portfolio
Revolution Medicines' Phase 3 in metastatic pancreatic cancer meets primary, key secondary endpoints
Revolution Medicines' Phase 3 RASolute 302 trial of daraxonrasib in metastatic pancreatic cancer meets all primary and key secondary endpoints with significant OS benefit
- Company plans to include RASolute 302 data in global regulatory filings, including a future FDA New Drug Application.
Subscribe to:
Posts (Atom)